These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28389847)

  • 1. A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Qin Y; Zhong Y; Ma T; Zhang J; Yang G; Guan F; Li Z; Li B
    Glycoconj J; 2017 Aug; 34(4):523-535. PubMed ID: 28389847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of abnormal fucosylated-glycans recognized by LTL in saliva of HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Zhang J; Zhong Y; Zhang P; Du H; Shu J; Liu X; Zhang H; Guo Y; Jia Z; Niu L; Yang F; Li Z
    Glycobiology; 2019 Mar; 29(3):242-259. PubMed ID: 30535277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of N- and O-linked glycans recognized by AAL in saliva of patients with atrophic gastritis and gastric cancer.
    Shu J; Yu H; Du H; Zhang J; Zhang K; Li X; Xie H; Li Z
    Cancer Biomark; 2018; 22(4):669-681. PubMed ID: 29865036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation.
    Nie H; Liu X; Zhang Y; Li T; Zhan C; Huo W; He A; Yao Y; Jin Y; Qu Y; Sun XL; Li Y
    Sci Rep; 2015 Nov; 5():16007. PubMed ID: 26537865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-linked glycan changes of serum haptoglobin β chain in liver disease patients.
    Zhang S; Shu H; Luo K; Kang X; Zhang Y; Lu H; Liu Y
    Mol Biosyst; 2011 May; 7(5):1621-8. PubMed ID: 21380457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of N-glycan expression profile and glycan pattern of glycoproteins in human hepatoma cells after HCV infection.
    Xiang T; Yang G; Liu X; Zhou Y; Fu Z; Lu F; Gu J; Taniguchi N; Tan Z; Chen X; Xie Y; Guan F; Zhang XL
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1036-1045. PubMed ID: 28229927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of site-specific N-glycans on sera haptoglobin β chain in liver diseases.
    Zhang S; Jiang K; Sun C; Lu H; Liu Y
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):1021-9. PubMed ID: 24103369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
    Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
    Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus.
    Liu XE; Desmyter L; Gao CF; Laroy W; Dewaele S; Vanhooren V; Wang L; Zhuang H; Callewaert N; Libert C; Contreras R; Chen C
    Hepatology; 2007 Nov; 46(5):1426-35. PubMed ID: 17683101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
    Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
    Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
    Ressom HW; Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R
    J Proteome Res; 2008 Feb; 7(2):603-10. PubMed ID: 18189345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.
    Cong M; Ou X; Huang J; Long J; Li T; Liu X; Wang Y; Wu X; Zhou J; Sun Y; Shang Q; Chen G; Ma H; Xie W; Piao H; Yang Y; Gao Z; Xu X; Tan Z; Chen C; Zeng N; Wu S; Kong Y; Liu T; Wang P; You H; Jia J; Zhuang H
    OMICS; 2020 Jul; 24(7):415-423. PubMed ID: 32522092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
    Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.
    Wang W; Zhao LJ; Wang Y; Tao QY; Feitelson MA; Zhao P; Ren H; Qi ZT
    Cancer Biomark; 2011-2012; 11(1):29-39. PubMed ID: 22820138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.
    Mondal G; Saroha A; Bose PP; Chatterjee BP
    Glycoconj J; 2016 Apr; 33(2):209-18. PubMed ID: 27034286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
    Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.